The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Predicting cytopenia in lymphoma patients treated with axi-cel
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses a study aiming to determine the rate of cytopenia in patients with large cell lymphoma (LCL) who have been treated with axicabtagene ciloleucel (axi-cel). An in-depth analysis of patient data was conducted, focusing on pre- and post- axi-cel treatment factors associated with cytopenia. The findings of this study show that severe cytopenia is common after axi-cel, especially in patients in need of subsequent therapies. Pre-CAR-T cytopenia and transfusion needs as well as post-CAR-T steroid use were identified as potential predictors of day 30 severe cytopenia in patients with LCL undergoing axi-cel treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
